Table 3. Leukemic burden after treatment with CAR-NK cells.
The values were digitized and estimated from figures, reported as mean ± SD when available/derivable; otherwise mean (range). NK: natural killer; CAR: chimeric antigen receptor; Ctrl: control; N.R: not reported; n.s: not significant; NT: no CAR transduction; PROD: Prodigy; SS: Small Scale; Tt: Time after treatment; (**) Only top bar reported; (†) Derived from SEM; (") p value taken from dot plot with individual points and mean or median, without error bars (reported as bar graph in the article).
| Study | Xenograft (cells) | Type of transplanted cells | Leukemic burden | ||||
| Treatment - Control | Tt | n | Total flux (p/s) | Statistical Test | p-value | ||
| Mean ± SD / (range) | |||||||
| Albinger et al. 2022 [29] | OCI-AML2 | CD33-CAR-NK (1 dose) | 21 | 7 | 1.2×108 (1x108 - 2x1010) | Median ± Range | N.R |
| Ctrl: NT-NK | 5×1010 (1.7x1010 - 2.4x109) | ||||||
| CD33-CAR-NK (3 doses) | 21 | 7 | 1.5×108 (1x108 - 4.8x108) | Median ± Range | N.R | ||
| Ctrl: NT-NK | 6 | 1.8×1010 (1.4x1010 - 2.7x1010) | |||||
| Albinger et al. 2024 [30] | OCI-AML2 | CD33-CAR-NK (PROD/ SS) | 18 | 9 | 8.7x100 (2.3x101) ** | Mean±SD | N.R |
| Ctrl 1: CD33-CAR-NK | 9 | 4.6x100 (5.7x101) ** | Mean±SD | ||||
| Ctrl: 2 NT-NK | 7 | 1.1x106 (8.2x108) ** | Mean±SD | ||||
| Caruso et al. 2022 [26] | THP-1 | CD123-CAR-NK | 50 | 4 | 5.4×105 (4.8x105 - 2.3x107) | Median ± Range | N.R |
| Ctrl 1: CD123-CAR-T | 4.4×105 (3.2x105 - 2.2x1010) | ||||||
| Ctrl 2: NT-NK | 30 | 5.5×109 (2.3 - 6.6x109) | |||||
| Christodoulou et al. 2021 [31] | MV-4-11 | CD123-2B4.ζ CAR-NK | 14 | (8-12) | 1.9×104 (5.3x103 - 9.4x104) | ANOVA | <0.01 |
| Ctrl 1: 4-1BB.ζ CARNK | 4.3×104 (1.1x104 - 9.5x104) | ||||||
| Ctrl 2: NT-NK | 1.2×105 (2.8x104 - 2.4x105) | <0.0001 | |||||
| 2B4.ζ/sIL-15 CAR-NK | 14 | (5-7) | 5.3×103 (2x103 - 1.2x104) | ANOVA | N.R | ||
| Ctrl 1: 2B4.ζ CARNK | 7.1×103 (1x103 - 2.3x104) | ||||||
| Ctrl 2: NT-NK | 1.4×105 (5.2x104 - 2.9x105) | <0.0001 | |||||
| MOLM-13 | 2B4.ζ/sIL-15 CAR-NK | 14 | 5 | 1.3×105 (1.6x104 - 2.8x105) | ANOVA | <0.0001 | |
| Ctrl 1: 2B4.ζ CARNK | 5.9×105 (4.3x105 - 8.4x105) | ||||||
| Ctrl 2: NT-NK | 7.3×106 (4x106 - 1.6x107) | <0.0001 | |||||
| Dong et al. 2022 [27] | OCI-AML3 | NPM1c-CAR-CIML NK | 10 | 4 | 2 ± 0.6 x108 † | ANOVA | 0.02 |
| Ctrl: NT-NK | 4.3 ± 0.4 x108 † | ||||||
| NPM1c-CARm15-NK | 18 | 4 | 5.3 ± 3.4 x108 † | ANOVA | 0.05 | ||
| Ctrl 1: NPM1c-CAR-NK | 11.2 ± 4.8 x108 † | ||||||
| Ctrl 2: NT-NK | 14.6 ± 7.4 x108 † | 0.05 | |||||
| NPM1c-CARm15-NK | 18 | 4 | 1.3 ± 1.2 x109 † | ANOVA | 0.49 | ||
| Ctrl 1: NPM1c-CAR-T | 1.2 ± 0.6 x109 † | ||||||
| Ctrl 2: NT-NK | 2.8 ± 1.2 x109 † | 0.001 | |||||
| Du et al. 2021 [32] | KG1 | NKG2D CAR-NK | 42 | 5 | 1.5×108 (1.4x108 - 1.6x108) | Median ± Range | N.R |
| Ctrl: NT-NK | 2.3×108 (1.9x108 - 2.9x108) | ||||||
| NKG2D CAR/IL15-NK (1 dose) | 17 | 6 | 2.5×103 (1.3x103 - 4.6x103) | N.R | <0.05 " | ||
| NKG2D CAR/IL15-NK (2 doses) | 4 | 2.3×103 (1x103 - 5.4x103) | |||||
| NKG2D CAR/IL15-NK (3 doses) | 4 | 5.1×103 (2.6x103 - 8.8x103) | |||||
| Ctrl 1: NKG2D CAR-NK | 6 | 6.7×105 (4.5x104 - 1.6x106) | |||||
| Ctrl 2: NT-NK | 5 | 2.7×106 (2.4x106 - 3.6x106) | <0.0001 " | ||||
| Mansour et al. 2023 [33] | MOLM-13 | FLT3 CAR_CD28/CD3ζ | 12 | 3 | 1.6 ± 0.52 x108 † | ANOVA | N.R |
| Ctrl1: CAR 2B4/CD3ζ | 2.3 ± 0.69 x108 † | ||||||
| Ctrl2: NT-NK-tCD19 | 5.3 ± 3.12 x108 † | <0.01 | |||||
| Morgan et al. 2021 [34] | LMA-PDX~ | CD123-CAR-hIL15-NK-92 (1 dose) | 14 | 7 | 39.2 ± 10 %† | Unpaired t-test | n.s |
| Ctrl: NT-NK92 | 4 | 32.9 ± 7.4 %† | |||||
| CD123-CAR-hIL15-NK-92 (2nd dose) | 21 | 7 | 19.8 ± 12.4 %† | Unpaired t-test | 0.05 | ||
| Ctrl: NT-NK92 | 4 | 61.9 ± 11.8 %† | |||||
| Salman et al. 2019 [35] | MOLM-13 | CD4-CAR-NK | 9 | 8 | 3.3 ± 2.8 x106 | N.R | < .00001 |
| Ctrl: NT-NK | 0 | ||||||